IBRX stock price forecast for Q3 2024 shows potential upside driven by immunotherapy pipeline milestones. Market analysts project a 12–15% price appreciation if upcoming Phase 2 trial data meets target endpoints, with resistance near $6. Companies discussed in this article include IBRX HIMS and SN . 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last year. There is currently 1 sell rating, 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IBRX shares. IBRX stock price forecast sentiment has improved following insider purchases disclosed in SEC filings. This behavior often precedes upward moves, with potential revaluation scenarios targeting $6.